11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment

To date, most diagnostic imaging comparisons between amyloid labelling ligands and other imaging modalities have been between the use of amyloid labelling ligand C Pittsburgh Compound B (PiB) and FDG-PET. Our objectives were to compare cognitive performance and diagnostic group-wise discrimination between cognitively normal, amnestic mild cognitive impairment (MCI) and Alzheimer’s disease subjects with MRIbased measures of hippocampal volume and PiB retention, and secondly to evaluate the topographic distribution of PiB retention and grey matter loss using 3D voxel-wise methods.Twenty cognitively normal, 17 amnestic MCI and 8 probable Alzheimer’s disease subjects were imaged with both MRI and PiB. PiB retention was quantified as the ratio of uptake in cortical to cerebellar regions of interest (ROIs) 40^60min post-injection. A global cortical PiB retention summary measure was derived from six cortical ROIs. Statistical parametric mapping (SPM) and voxel-based morphometry (VBM) were used to evaluate PiB retention and grey matter loss on a 3D voxel-wise basis. Alzheimer’s disease subjects had high global cortical PiB retention and low hippocampal volume; most cognitively normal subjects had low PiB retention and high hippocampal volume; and on average amnestic MCI subjects were intermediate on both PiB and hippocampal volume. A target-to-cerebellar ratio of 1.5 was used to designate subjects with high or low PiB cortical retention. All Alzheimer’s disease subjects fell above this ratio, as did 6 out of 20 cognitively normal subjects and 9 out of17 MCI subjects, indicating bi-modal PiB retention in the latter two groups. Interestingly, we found no consistent differences in learning and memory performance between high versus low PiB cognitively normal or amnestic MCI subjects. The SPM/ VBM voxel-wise comparisons of Alzheimer’s disease versus cognitively normal subjects provided complementary information in that clear and meaningful similarities and differences in topographical distribution of amyloid deposition and grey matter loss were shown.The frontal lobes had high PiB retention with little grey matter loss, anteromedial temporal areas had low PiB retention with significant grey matter loss, whereas lateral temporoparietal association cortex displayed both significant PiB retention and grey matter loss. A voxel-wise SPM conjunction analysis revealed that subjects with high PiB retention shared a common PiB retention topographical pattern regardless of clinical category, and thismatched that of amyloid plaque distribution from autopsy studies of Alzheimer’s disease. Both global cortical PiB retention and hippocampal volumes demonstrated significant correlation in the expected direction with cognitive testing performance; however, correlations were stronger with MRI than PiB. Pair-wise inter-group diagnostic separation was significant for all group-wise pairs for both PiB and hippocampal volume with the exception of the comparison of cognitively normal versus amnestic MCI, which was not significant for PiB. PiB and MRI provided complementary information such that clinical diagnostic classification using both methods was superior to using either in isolation.

[1]  A. Hirano,et al.  Alzheimer's neurofibrillary changes. A topographic study. , 1962, Archives of neurology.

[2]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[3]  P. McCullagh Regression Models for Ordinal Data , 1980 .

[4]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[5]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[6]  C. Jack,et al.  Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. , 1989, Radiology.

[7]  Gwenn S. Smith,et al.  EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.

[8]  E. Tangalos,et al.  Mayo Clinic Alzheimer’s Disease Patient Registry , 1990, Aging.

[9]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[10]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[11]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[12]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[13]  M. Albert,et al.  Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. , 1993, Archives of neurology.

[14]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[15]  M. Sliwinski,et al.  Pathological markers associated with normal aging and dementia in the elderly , 1993, Annals of neurology.

[16]  B. Hyman,et al.  The Lack of Accumulation of Senile Plaques or Amyloid Burden in Alzheimer's Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution , 1993, Journal of neuropathology and experimental neurology.

[17]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[18]  P C O'Brien,et al.  Procedures for setting normal values , 1995, Neurology.

[19]  C. Kawas,et al.  Neuropathology in controls and demented subjects from the Baltimore longitudinal study of aging , 1996, Neurobiology of Aging.

[20]  Nick C Fox,et al.  Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. , 1996, Brain : a journal of neurology.

[21]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[22]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[23]  J. Kaye,et al.  Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia , 1997, Neurology.

[24]  C. Jack,et al.  Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.

[25]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[26]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[27]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[28]  Cees Jonker,et al.  Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment , 1999, Journal of Neurology.

[29]  Thomas E. Nichols,et al.  Comparative evaluation of MR-based partial-volume correction schemes for PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[31]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[32]  J. Ashford,et al.  “Preclinical” AD revisited , 2000, Neurology.

[33]  Frederik Barkhof,et al.  Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease , 2000, Neuroscience Letters.

[34]  Jeffrey A. Kaye,et al.  The Oregon Brain Aging Study , 2000, Neurology.

[35]  J. Baron,et al.  In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease , 2001, NeuroImage.

[36]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[37]  Nick C Fox,et al.  Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images , 2001, The Lancet.

[38]  B T Hyman,et al.  Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy , 2001, The Journal of Neuroscience.

[39]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[40]  W. Markesbery,et al.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study , 2002, Annals of neurology.

[41]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[42]  M. Albert,et al.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD , 2002, Neurology.

[43]  W. Markesbery,et al.  Hippocampal volume as an index of Alzheimer neuropathology: Findings from the Nun Study , 2002, Neurology.

[44]  J. Baron,et al.  Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment , 2002, Neuroreport.

[45]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[46]  Thomas E. Nichols,et al.  Thresholding of Statistical Maps in Functional Neuroimaging Using the False Discovery Rate , 2002, NeuroImage.

[47]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[48]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[49]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[50]  Ronald C Petersen,et al.  Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. , 2003, Archives of neurology.

[51]  J. Quinn,et al.  Changes in premorbid brain volume predict Alzheimer’s disease pathology , 2003, Neurology.

[52]  Lei Wang,et al.  Correlations Between Antemortem Hippocampal Volume and Postmortem Neuropathology in AD Subjects , 2004, Alzheimer disease and associated disorders.

[53]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[54]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[55]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[56]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[57]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[58]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  Clifford R. Jack,et al.  Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease , 2005, NeuroImage.

[60]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  Jesper Andersson,et al.  Valid conjunction inference with the minimum statistic , 2005, NeuroImage.

[62]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[63]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[64]  W. Markesbery,et al.  Recent Clinical-Pathologic Research on the Causes of Dementia in Late Life: Update From the Honolulu-Asia Aging Study , 2005, Journal of geriatric psychiatry and neurology.

[65]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[66]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[67]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[68]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[69]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[70]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[71]  Clifford R Jack,et al.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.

[72]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[73]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[74]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[75]  B. L. Miller,et al.  11 CPIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007 .

[76]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[77]  William J. Jagust,et al.  Automated template-based PET region of interest analyses in the aging brain , 2007, NeuroImage.

[78]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[79]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[80]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[81]  C. Jack,et al.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment , 2008, Neurology.

[82]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.